Bleeding, clotting, and functional disability following Beall prosthetic mitral valve replacement

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Clinical Medicine

Background:

• Beall mitral valve replacement necessitates anticoagulation to prevent thromboembolic events.
• The efficacy and safety of sodium warfarin in this patient population require ongoing evaluation.

Purpose of the Study:

• To compare the incidence of thromboemboli and bleeding in patients with Beall mitral valve replacement receiving sodium warfarin versus those not receiving it.
• To assess the impact of anticoagulation quality on outcomes and evaluate postoperative exercise capacity.

Main Methods:

• Retrospective comparison of thromboembolic and bleeding episodes in patients with and without sodium warfarin post-Beall mitral valve replacement.
• Actuarial analysis of event incidence and correlation of prothrombin times with hemorrhagic complications.
• Pre- and post-operative treadmill exercise tests to evaluate functional capacity.

Main Results:

• Patients not receiving sodium warfarin had a significantly higher incidence of emboli (P < 0.01) and combined emboli/hemorrhage (P < 0.05).
• Fatal outcomes from emboli or hemorrhage did not differ significantly between groups.
• Hemorrhagic episodes were strongly associated with excessive anticoagulation (prothrombin times > 3-8 times control).
• Significant improvement in exercise tolerance was observed post-surgery, but capacity remained suboptimal (55-57% of controls).

Conclusions:

• Sodium warfarin therapy is supported for Beall mitral valve replacement patients, emphasizing strict anticoagulation control.
• Residual impairment in physical working capacity persists despite surgical intervention and anticoagulation.